aibioOragenics names John Spencer CFO and reports annual meeting votes
Tickers OGEN
Oragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.
Key facts
- Company
- Oragenics Inc. (AMEX: OGEN)
- News type
- Listings
- Primary source
- Oragenics Inc. 8-K (2026-07-06)
Oragenics, Inc. (NYSE American: OGEN) appointed John Spencer as its Chief Financial Officer effective July 1, 2026. The board made the appointment, and the company reported it in a Form 8-K dated July 6, 2026. The filing was signed by Janet Huffman, Chief Executive Officer.
Under an Executive Employment Agreement effective July 1, 2026, Mr. Spencer receives base compensation of $200,000. He also received an option award equal to $25,000, with an exercise price equal to the closing price of the company's common stock on NYSE American immediately before the grant. The company says there are no current or proposed transactions with him or his immediate family that would require disclosure under Item 404(a).
Mr. Spencer's background
Mr. Spencer, age 32, joined the company in April 2025 as Senior Controller and has led its finance and accounting organization. His duties include SEC reporting, treasury, budgeting and internal controls. From March 2022 through April 2025, he operated a fractional chief financial officer and financial consulting practice serving public and private companies.
Before joining Oragenics, Mr. Spencer was Vice President of Finance at Trxade Health, Inc., a publicly traded healthcare technology company. He began his career at PricewaterhouseCoopers LLP, providing audit and tax services. He is a Certified Public Accountant in Florida and holds a Master of Accountancy and a Bachelor of Science in Accounting from the University of South Florida.
Annual meeting votes
Shareholders met on June 29, 2026. Six directors were re-elected: Charles Pope, Dr. Frederick Telling, Mr. Robert Koski, Dr. Alan Dunton, Mr. John Gandolfo and Ms. Natasha Giordano. Pope received 1,017,697 votes for and 292,270 withheld. Telling received 1,018,895 for and 291,072 withheld. Dunton received 1,016,221 for and 293,746 withheld. Giordano, the lowest, received 984,704 for and 325,263 withheld. Broker non-votes were 793,522 for each director.
On the non-binding advisory vote on executive compensation, 806,898 votes were cast for, 478,522 against and 24,545 abstained, with 793,522 broker non-votes. Shareholders ratified Cherry Bekaert LLP as independent auditors for the year ending December 31, 2026, with 1,887,381 votes for, 184,883 against and 31,225 abstaining.
The reverse split proposal
Shareholders also voted on a proposal to authorize the board to enact a reverse stock split, in its sole discretion, at any time within one year after shareholder approval. The ratio would be not less than one-for-two (1:2) and not greater than one-for-fifty (1:50). The filing reports 1,239,961 votes for, 836,159 against and 27,366 abstentions. The filing lists the vote counts but does not state whether the proposal passed.
Company background
The 10-K describes ONP-002, the company's lead candidate, as a fully synthetic, non-naturally occurring neurosteroid for the treatment of mild traumatic brain injury, also called concussion. The drug is manufactured as a powder and filled into a novel intranasal device that is breath-propelled. The company says the device is designed to trap ONP-002 in the nasal cavity.
The company says ONP-002 has been shown to be stable up to 104 degrees for 18 months.
Financial position
According to the 10-K, research and development expense was $2.4 million in 2025, compared with $4.1 million in 2024. Net loss was $9.8 million in 2025 and $10.6 million in 2024. Cash used in operations was $9.2 million in 2025 and $8.6 million in 2024. Year-end cash and cash equivalents were $864,840 at December 31, 2024.
This story uses only figures from filings made on or before July 6, 2026, so it does not cite the company's later quarterly balances.
What comes next
The filing does not describe steps beyond the appointment and the vote results. The votes show dissent: 478,522 shares were cast against the pay proposal and 836,159 against the reverse split. The filing states no reason for the reverse split authority and no plan to use it. The new finance chief, who is 32, takes over a company that used $9.2 million of cash in operations in 2025.